<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5890">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03030274</url>
  </required_header>
  <id_info>
    <org_study_id>Occ2016_06</org_study_id>
    <nct_id>NCT03030274</nct_id>
  </id_info>
  <brief_title>Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator (AFR) in Heart Failure Patients</brief_title>
  <acronym>PRELIEVE</acronym>
  <official_title>Prospective, Non-randomized, Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator (AFR) in Heart Failure Patients With Reduced Ejection Fraction or in Heart Failure Patients With Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Occlutech International AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Occlutech International AB</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate safety and efficacy of Occlutech® AFR device in patients with
      HFrEF (Heart failure with reduced ejection fraction) and HFpEF (Heart failure with preserved
      ejection fraction)
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2017</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious Adverse Device Effects (SADE) within 3 month following implantation.</measure>
    <time_frame>0-3 month</time_frame>
    <description>Incidence of Serious Adverse Device Effects (SADE) following implantation such as:
device dislocation / embolization
damage to the tricuspid or mitral valve caused by the device
intractable arrhythmias caused by the device
any circumstances that require device removal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Device Effects (SADE) between 3-12 month following implantation</measure>
    <time_frame>3-12 month</time_frame>
    <description>Incidence of all Serious Adverse Device Effects (SADE) following implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device placement</measure>
    <time_frame>0-12 month</time_frame>
    <description>Device placement in situ or not in situ (as assessed by investigator)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left to Right shunt through the AFR device</measure>
    <time_frame>0-12 month</time_frame>
    <description>Evidence of Left to Right shunt through the AFR device as assessed by echocardiography and/or fluoroscopy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Heart Failure Low Output</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Occlutech AFR Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Occlutech AFR device</intervention_name>
    <description>Catheter-guided placement of an AFR device following balloon atrial septostomy.</description>
    <arm_group_label>Occlutech AFR Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 years

          2. NYHA (New York Heart Association) class III or IV

          3. Ongoing management of heart failure according to ESC (European Society of Cardiology)
             guidelines during previous ≥6 months

          4. Symptomatic heart failure resulting in at least one hospitalization in the past 12
             months

          5. Absence of significant (more than moderate) valvular disease (AS(Aortic stenosis), MS
             (Mitral valve stenosis), MR)

          6. Control of arrhythmia with heart rate &lt;90bpm

          7. Life expectancy of at least 1 year

          8. The patient or his/her legal representative should have the ability to fluently speak
             and under-stand the language in which the study is being conducted

          9. Written, informed consent by the patient for participation in the study and agreement
             to comply with the follow-up schedule

         10. Patient has had a successful Balloon Atrial Septostomy (BAS) procedure and is in a
             stable hemodynamic state, as assessed by the investigator

             Echo data:

         11. LVEF (Left ventricular ejection fraction) ≤ 55%

         12. Elevated left ventricular filling pressure documented by

               -  Either Pulmonary capillary wedge pressure (PCWP) or left ventricular
                  end-diastolic pres-sure at rest ≥15 mmHg and greater than central venous
                  pressure (CVP)

               -  Or: End-expiratory PCWP ≥25 mmHg at exercise and CVP &lt;20 mm Hg

         13. Transseptal catheterization and femoral vein access is determined to be feasible

             Exclusion Criteria:

         14. Local or generalized sepsis or other acute infection(s)

         15. Any coagulation disorder, if clinically relevant in the opinion of the operator.

         16. Known Allergy to nickel and/or titanium and/or nickel/titanium-based materials, if
             not medically manageable.

         17. Allergy to anti-platelet, -coagulant, or -thrombotic therapy, if not medically
             manageable

         18. Intolerance to contrast agents, if not medically manageable

         19. Participation in another medical trial testing a therapy less than 30 days before the
             intended AFR implantation procedure

         20. Trans-oesophageal echocardiography and / or use of general anaesthetic is
             contraindicated

         21. Breast feeding women

         22. Pregnancy - (assessed in patients with child bearing potential by urine dip stick)

         23. Occluded inferior vena cava access

         24. History of ASD (Atrial septal defect) and/or atrial septal repair or closure device
             in place

         25. Intracardiac thrombus

         26. Patients who has unstable and intractable angina pectoris

         27. Evidence of right heart failure defined as (by ECHO)

               -  Severe Right Ventricular Dysfunction (Tricuspid annular plane systolic excursion
                  (TAPSE) &lt; 14 mm)

               -  Severe Right Ventricular Dilatation ( Right ventrical (RV) volume ≥ left
                  ventrical (LV) volume)

               -  Severe pulmonary hypertension (pulmonary arterial systolic pressure (PASP) &gt; 70
                  mm Hg)

         28. Active malignancy

         29. Severe valve disease, or implanted mechanical valve prosthesis

         30. Congenital heart defect

         31. Large Patent Foramen Ovale (PFO) with significant atrial septal aneurysm

         32. Resting heart rate &gt;110 bpm

         33. Inability to perform 6-minutes walking test

         34. Clinically relevant thrombocytopenia, thrombocytosis, leukopenia, or anemia

         35. Symptomatic carotid artery disease

         36. Mitral valve stenosis

         37. Has any condition that, in the opinion of the Investigator, might interfere with the
             implantation, might affect the patients well-being thereafter or might interfere with
             the conduct of the study

         38. Systolic blood pressure of &gt;170 mmHg on 24 hour ambulatory blood pressure monitoring
             (ABPM), despite medical therapy

         39. Severe lung disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 23, 2017</lastchanged_date>
  <firstreceived_date>January 17, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
